Evidence map›Paper›PMID 39712472›Full record

ArticleFrontiers in artificial intelligence2024

Explainable machine learning for predicting recurrence-free survival in endometrial carcinosarcoma patients.

Samantha Bove, Francesca Arezzo, Gennaro Cormio, Erica Silvestris, Alessia Cafforio, Maria Colomba Comes, Annarita Fanizzi, Giuseppe Accogli, Gerardo Cazzato, Giorgio De Nunzio and 6 more

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Samantha Bove *Laboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Francesca Arezzo *Ginecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Gennaro CormioGinecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Erica SilvestrisGinecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Alessia CafforioDipartimento Interdisciplinare di Medicina (DIM), Università degli Studi di Bari "Aldo Moro", Bari, Italy.
Maria Colomba ComesLaboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Annarita FanizziLaboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Giuseppe AccogliLaboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Gerardo CazzatoDipartimento dell'Emergenza e dei Trapianti di Organi, Università degli Studi di Bari "Aldo Moro", Bari, Italy.
Giorgio De NunzioLaboratory of Biomedical Physics and Environment, Department of Mathematics and Physics "E. De Giorgi", Università del Salento, Lecce, Italy.
Brigida MaioranoOncologica Medica, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Emanuele NaglieriGinecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Andrea LupoLaboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Elsa VitaleDirezione Scientifica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Vera Loizzi *Ginecologia Oncologica, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Raffaella Massafra *Laboratorio di Biostatistica e Bioinformatica, Fisica Sanitaria, I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Endometrial carcinosarcoma is a rare, aggressive high-grade endometrial cancer, accounting for about 5% of all uterine cancers and 15% of deaths from uterine cancers. The treatment can be complex, and the prognosis is poor. Its increasing incidence underscores the urgent requirement for personalized approaches in managing such challenging diseases. Method: In this work, we designed an explainable machine learning approach to predict recurrence-free survival in patients affected by endometrial carcinosarcoma. For this purpose, we exploited the predictive power of clinical and histopathological data, as well as chemotherapy and surgical information collected for a cohort of 80 patients monitored over time. Among these patients, 32.5% have experienced the appearance of a recurrence. Results: The designed model was able to well describe the observed sequence of events, providing a reliable ranking of the survival times based on the individual risk scores, and achieving a C-index equals to 70.00% (95% CI, 59.38-84.74). Conclusion: Accordingly, machine learning methods could support clinicians in discriminating between endometrial carcinosarcoma patients at low-risk or high-risk of recurrence, in a non-invasive and inexpensive way. To the best of our knowledge, this is the first study proposing a preliminary approach addressing this task.

Indexed as

endometrial carcinosarcomaexplainable artificial intelligencemachine learningpersonalized medicinerecurrence-free survival

Identifiers

PMID39712472
PMCPMC11659245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.